Multiple Sclerosis Resource Centre
  • Home
  • MSRC Grand Opening 30/05/12
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • Welcome To Josephs Court, MS Centre Of Excellence
  • Advertising
  • Best Bet Diet Group
  • E-Newsletter
  • Contact Us
  • Investor in People
    You are here : Home » MS Research News » New Discoveries » CRMP-2

    CRMP-2

    A A A
    [Print this page]

    Share |


    Protein block `could halt multiple sclerosis`

    MS MRIScientists claim to have discovered that the progress of debilitating disease multiple sclerosis could be slowed or even stopped by blocking a protein which contributes to nerve damage.

    An international team has shown that the key role played by the collapsing response mediator protein 2 (CRMP-2)) in the development of multiple sclerosis (MS), the `Brain` journal reported.

    In their research, the scientists found that a modified version of CRMP-2 is present in active MS lesions, which indicate damage to the nervous system, in a laboratory model of MS.

    The modified CRMP-2 interacts with another protein to cause nerve fibre damage that can result in numbness, blindness, difficulties with speech and motor skills, and cognitive impairments in sufferers.

    When either the modified CRMP-2 or the interaction between the two proteins was blocked, using a method already approved in both the US and Australia, the progression of the disease was halted.

    The scientists say that the discovery could lead to new treatments for MS.

    "Blocking the same protein in people with MS could provide a `handbrake` to the progression of the disease," Prof Richard Boyd of Monash University, a team member, said.

    Dr Steven Petratos, the team leader, said the method used to block the protein was approved for the treatment of other disease conditions by both the US Food and Drug Administration and Australia's Therapeutic Goods Administration.

    "This should mean that clinical trials -- once they start -- will be fast tracked as the form of administration has already been approved," he added.

    Source: ZeeNews.com © 1998-2012 Zee News Limited (30/04/12)

    © Multiple Sclerosis Resource Centre

    Related Items
    Abnormal Liver Tests and MS
    AlphaB-crystallin
    Aluminium and Multiple Sclerosis
    Antagonist compounds
    Antibodies, B Cells,T-Cell Activation, Immune Response
    Apolipoprotein D
    Bacteria & MS
    Biomarkers and MicroRNA
    Blood tests
    Bone Marrow Cells and MS Treatment
    Bowmann-Birk Inhibitor Concentrate (BBIC)
    Brain Atrophy, Lesion Loads, White and Grey Matter
    Brain Inflammation
    Brain Iron Deposits
    Calcium Binding Proteins
    Cerebro-Spinal Fluid & Spinal Cord
    Chronic Cerebrospinal Venous Insufficiency (CCSVI)
    CXCL1, 7, 12
    Cytokines & Chemokines
    Dendritic Cells
    Estrogen Receptors
    Fibrinogen, Mac-1 and Microglia
    HDL
    HERV-Fc1
    Histamine and MS
    Hormones And MS Research
    Immunoglobulins
    Infections and Multiple Sclerosis Relapses
    Interleukin-1beta
    JAK-STAT inhibitors
    Kallikrein 6
    Lipids & MS
    Medical Imaging
    Mycoplasmas And Bacteria
    N-acetylglucosamine (GlcNAc) & Glucosamine
    Natural Interferon Beta
    Natural Killer Cells
    Nerve and Brain Cell Research
    Neurosteroids
    Olig 1 Gene Discovery
    Oligodendrocytes and Astrocytes
    Pesticides and Multiple Sclerosis
    PKC-theta
    Plasma Exchange
    Potential Viral Causes of MS
    Proteomics
    Recombinant Human Erythropoietin
    Regeneration Research
    RNA and RNAi
    Synthetic Small Molecules
    Technology
    Tetanus Vaccine and Possible MS Protection
    Tetramers
    The Blood Brain Barrier
    Tremors And MS
    Uric Acid
    Urinary Problems
    Vascular Function And MS
    Vision and MS


    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.